AGF Management’s Genmab GMAB Stock Holding History

AGF Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,056	Closed	-$279K	–	657
2025 Q4	$279K	Hold	9,056	–	–	﹤0.01%	632
2025 Q3	$278K	Buy	+9,056	New	+$221K	﹤0.01%	628

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

AGF Management's GMAB Position: Q1 2026 in Review

AGF Management sold out of Genmab (GMAB) in Q1 2026, closing a stake of 9,056 shares — an estimated $279K sold.

AGF Management first reported a position in GMAB in Q3 2025 and held it in 2 quarters. The position peaked at $279K in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

AGF Management reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
AGF Management sold 9,056 Genmab shares in Q1 2026, an estimated $279K.
AGF Management first reported a position in Genmab in Q3 2025 and held it in 2 quarters.
AGF Management's Genmab position peaked at $279K in Q4 2025.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on AGF Management's 13F filing for Q1 2026, filed 7 May 2026.